

## 42nd Annual Oregon Rural Health Conference

October 1-3, 2025





### Expanding Access: The Role of Pharmacists in Prescription Renewals

Nathan Wende, PharmD, Director of Clinical and Consulting Services

Medication Review

# Expanding Access: The Role of Pharmacists in Prescription Renewals

Nathan Wende, PharmD – Director of Clinical and Consulting Services



### **Introduction & Context**

- Provider shortages & rising demand
- Chronic disease management requires timely refills
- Delays harm adherence & outcomes
- Objectives: Scope, benefits, strategies



### Regulatory & Legal Framework

- State variations in pharmacist authority
- Collaborative Practice Agreements (CPAs)
- Standing orders & independent renewals
- Liability, documentation, patient consent



### Clinical & Operational Benefits

- Patients: Improved adherence & access
- Providers: Reduced administrative burden
- Health systems: Cost savings & better-quality metrics




### **Workflow Model**

- Community pharmacy renewals
- Clinic-embedded pharmacists
- Telehealth & digital pharmacy models



#### Renewal Workflow





- Study Overview
- Design: Retrospective cohort, pre-post comparison.
- Setting: UC San Diego Health, Family Medicine & Internal Medicine clinics.
- Duration: Jan 2017–Dec 2018 (12 months pre vs 12 months post).
- Staffing: 1 pharmacist + 2 technicians, serving ~20% of primary care sites.
- Scope (under collaborative practice agreement):
  - Renew select chronic meds.
  - Initiate prior authorizations for noncontrolled meds.
  - Order labs (BMP, lipid, thyroid, A1C, etc.) and request follow-up visits.



Table 1 Physician efficiency scores

EHR metric	Clinic 1 (n = 15)				Clinic 2 (n = 7)			
	Baseline (CY 2017) (mean ± SD)	RPAPP (CY 2018) (mean ± SD)	Change from baseline	P value	Baseline (CY 2017) (mean ± SD)	RPAPP (CY 2018) (mean ± SD)	Change from baseline (mean ± SD)	P value
% of EHR messages not completed within 24 h	26.9 ± 2.56	22.9 ± 2.25	-4.0	0.001	19.4 ± 3.72	17.7 ± 3.78	-1.7	0.300
% of EHR results not viewed or addressed within 72 h	36.7 ± 3.66	36.5 ± 4.77	-0.2	0.918	33.7 ± 2.37	34.3 ± 5.56	+9.6	0.733
% of EHR office visit encounters not completed on the same day as visit	68.1 ± 3.81	61.2 ± 4.82	-6.9	0.001	24.3 ± 4.13	29.0 ± 6.68	+4.7	0.059
% of EHR patient telephone call encounters not completed within 24 h	38.8 ± 2.26	33.3 ± 3.29	-5.5	< 0.001	29.2 ± 3.78	37.9 ± 5.15	+8.7	< 0.001
% of EHR patient prescription (Rx) renewal requests not completed within 24 $$ h	15.9 ± 2.24	16.2 ± 2.64	-0.2	0.782	6.5 ± 2.51	10.7 ± 3.13	+14.2	0.002
Average efficiency score	39.1 ± 1.15	35.9 ± 2.90	-3.22	0.003	23.6 ± 2.07	28.1 ± 3.67	+4-45	0.002

Abbreviations used: EHR, electronic health record; CY, current year; RPAPP, refill and prior authorization pilot program.



- Shows sharp reductions in physicians working outside of hours on refill tasks:
- "Frequently/Always" dropped from ~70% to ~10%.
- "Never/Rarely" rose from ~15% to ~47%.




Figure 1 Physician frequency of time spent outside of normal work hours. Abbreviation used: RPAPP, refill an 0.001, N = 20 at baseline, n = 30 at 12 months.



#### Overworked feelings:

•Baseline: 70% "Frequently/Always."

•After 12 mo: 10%.

#### •Satisfaction with refill workload:

•Baseline: only 10% satisfied.

•After 12 mo: 6% satisfied/extremely satisfied.




Figure viewer

Figure 2 Physician refill workload contributing to feeling overworked. P < 0.001, N = 20 at baseline, N = 30 at 12 months.



		Results				
Measure Clinic		Baseline %	RPAPP %	Change %	P value	
Two hemoglobin A1Cs	Clinic 1	54-4	62.5	+8.12	0.009	
	Clinic 2	61.9	61.7	-o.26	0.93	
ACEI/ARB, diuretic monitoring	Clinic 1	77.8	81.0	+3.22	0.006	
	Clinic 2	82.6	83.9	+0.84	0.47	
Medical attention for nephropathy	Clinic 1	91.7	91.4	-0.25	0.88	
	Clinic 2	91.2	92.2	+0.97	0.55	

Table 2

CMS star measures results

Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; RPAPP, refill and prior authorization pilot; A1C, glycosylated hemoglobin.



#### **Productivity**

- •21,175 refills processed (90% independently by pharmacist).
- → ~700 physician hours saved (assuming 2 min/request).
- •1,550 PAs processed (70% approval).
- $\rightarrow$  ~770 staff hours saved (30 min/PA).
- •357 PAs avoided via pharmacist substitutions.
- •3,000+ lab orders and 3,300 follow-up appointments initiated



#### **Key Implications**

- •RPAPP reduced after-hours physician work and overwork perception.
- •Physician/staff satisfaction increased substantially.
- •Positive movement on CMS Star quality measures.
- •Freed hundreds of hours of physician and staff time.
- •Limitations: Uneven clinic results; potential survey bias; not revenue-generating but demonstrates strong value in quality-based care models.



•Setting: Multi-site FQHC in Los Angeles, serving >22,000 patients annually (>70% racial/ethnic minorities; majority low income, Medicaid-covered).

•PCPs: ~12.5 full-time equivalents.

•Duration: Sept 2020 – Aug 2021.

•Staffing: Pharmacists and supervised trainees working under a collaborative practice agreement.

•Workflow: Pharmacists reviewed refill requests, checked EHR med list, monitored need for labs or visits, and recommended interventions



•Setting: Multi-site FQHC in Los Angeles, serving >22,000 patients annually (>70% racial/ethnic minorities; majority low income, Medicaid-covered).

•PCPs: ~12.5 full-time equivalents.

•Duration: Sept 2020 – Aug 2021.

•Staffing: Pharmacists and supervised trainees working under a collaborative practice agreement.

•Workflow: Pharmacists reviewed refill requests, checked EHR med list, monitored need for labs or visits, and recommended interventions



#### **Service Volume & Efficiency**

•Refill requests addressed: 1,683 (1255 encounters).

•Proportion of total clinic volume: 9.2%.

•Productivity: 10.1 requests / 7.5 encounters per hour.

•Time commitment: ~3.2 hrs/week per pharmacist.

•Turnaround time: 87.8% completed within 48 hrs

**Table 1.** Selected Patient Characteristics For Encounters That Included One or More Intervention(s) [N = 407].

Mean age	55.5 years (range 18-89 years)
Female	53.1% (n=241)
Residency clinic patients	47.9% (n = 229)






Figure 2. Pharmacist refill interventions by type [N = 642].

#### **Pharmacist Interventions**

- •Encounters with interventions: 453 (36.1%).
- •Total interventions: 642.
- •Types of interventions
  - Follow-up visit due 32.9% (n=211)
  - Lab due 31.9% (n=205)
  - Drug therapy problem (DTP) 12.6% (n=81)
  - Med list discrepancy 11.9% (n=76)
  - Referral to pharmacy clinic 7.2% (n=46)
  - Other/coverage clarification 3.4%



#### **Drug Therapy Problems**

DTP Category	n (%)	Examples
Dosage too low	20 (24.1%)	Titration/renal dosing adjustments
Requires different drug	18 (21.7%)	Diabetes med switches to guideline-preferred agents
Dosage too high	17 (20.5%)	Safety adjustments
Unnecessary therapy	17 (20.5%)	Stopping aspirin in low-risk patients
Requires additional therapy	6 (7.2%)	Adding statin for ASCVD prevention
Non-adherence	3 (3.6%)	Missed meds
Adverse drug reaction	1 (1.2%)	Creatinine rise on lisinopril

#### **Resolution of DTPs**

•Resolved/addressed: 37.3% (n=31)

•Not addressed: **55.4%** (**n=46**)

•Indeterminate/lost to follow-up: 7.2% (n=6)



#### **Key Conclusions**

- •Feasibility: One pharmacist FTE could manage refill needs for a moderately sized FQHC (~120k visits/year).
- •Impact: Pharmacists identified clinically important issues (dosing, unnecessary meds, med list errors).
- •Continuity: High rates of lab/follow-up interventions support safe care and adherence.
- •Limitation: Over half of DTP recommendations were not acted on within 3 months, showing need for stronger pharmacist authority or follow-up systems



### **Challenges & Barriers**

- Regulatory variability across states
- Provider acceptance & trust
- Reimbursement limitations
- Technology & EHR access gaps



### Implementation Strategies

- Build collaborative protocols
- Use decision support tools & EHR integration
- Train pharmacists in chronic disease management
- Pilot programs with clear metrics



### **Future Directions**

- Provider status legislation
- Expansion of telepharmacy
- Al & automation support
- Pharmacists as primary access points



### Questions



